SkyOak Wealth LLC Makes New Investment in Medpace Holdings, Inc. (NASDAQ:MEDP)

SkyOak Wealth LLC acquired a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 833 shares of the company’s stock, valued at approximately $277,000.

A number of other large investors have also modified their holdings of MEDP. SYM FINANCIAL Corp purchased a new stake in shares of Medpace during the fourth quarter worth approximately $320,000. Tokio Marine Asset Management Co. Ltd. acquired a new position in Medpace during the 4th quarter worth approximately $9,335,000. China Universal Asset Management Co. Ltd. increased its position in shares of Medpace by 10.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,590 shares of the company’s stock valued at $2,189,000 after purchasing an additional 627 shares during the last quarter. Chicago Partners Investment Group LLC acquired a new stake in shares of Medpace in the 4th quarter valued at $298,000. Finally, Custom Index Systems LLC lifted its position in shares of Medpace by 3.0% during the 4th quarter. Custom Index Systems LLC now owns 1,290 shares of the company’s stock worth $429,000 after purchasing an additional 37 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $349.15 on Monday. The firm has a market cap of $10.85 billion, a price-to-earnings ratio of 30.57, a PEG ratio of 1.79 and a beta of 1.36. Medpace Holdings, Inc. has a 1 year low of $286.76 and a 1 year high of $459.77. The stock’s 50-day simple moving average is $342.50 and its 200-day simple moving average is $351.96.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Truist Financial lowered their price objective on Medpace from $415.00 to $397.00 and set a “hold” rating for the company in a research report on Monday, October 14th. Redburn Atlantic assumed coverage on Medpace in a report on Monday, October 14th. They issued a “buy” rating and a $404.00 price target for the company. Robert W. Baird raised their price objective on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Baird R W cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Finally, TD Cowen cut their price target on shares of Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $381.44.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.